MariTide Phase 2 obesity data show up to 20% weight loss at one year
100% citation coverage1 peer-reviewed sources
Amgen’s MariTide phase 2 obesity data showed up to 20% average weight loss at 52 weeks in participants without type 2 diabetes. The trial also reported up to 17% average weight loss in participants with type 2 diabetes, with placebo results provided in the published data.
Intelligence Snapshot
Executive Summary
MariTide achieved up to ~20% average weight loss at 52 weeks in people with obesity without Type 2 diabetes , compared with 2.6% in placebo.
Key Insights
-
In the obesity-with-Type 2 diabetes cohort, MariTide showed up to ~17% average weight…
In the obesity-with-Type 2 diabetes cohort, MariTide showed up to ~17% average weight loss versus 1.4% placebo.
- MariTide is dosed monthly or less frequently .
-
Amgen is running Phase 3 trials in obstructive sleep apnea , cardiovascular outcomes, and…
Amgen is running Phase 3 trials in obstructive sleep apnea , cardiovascular outcomes, and heart failure with preserved or mildly reduced ejection fraction.
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | high |
| Investment | medium |
Loading intelligence…
Quick Answer
MariTide achieved up to ~20% average weight loss at 52 weeks in people with obesity without Type 2 diabetes , compared with 2.6% in placebo.
Key Questions
- What weight loss did MariTide show in the Phase 2 trial?
- What is once-monthly maridebart cafraglutide for the treatment of obesity?
- What Phase 3 trials is Amgen running with MariTide?
- What was the placebo weight loss in the Phase 2 trial?
Executive Scorecard
Heuristic scores · directional, not investment adviceRegulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for MariTide.
Unlock full calendar →Amgen pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Contents10 sections
MariTide Phase 2 obesity data show up to 20% weight loss at one year
Amgen's MariTide phase 2 obesity data showed up to 20% average weight loss at 52 weeks in participants without type 2 diabetes. The trial also reported up to 17% average weight loss in participants with type 2 diabetes, with placebo results provided in the published data.
IntelligenceRegulatory Impact
FDA and EMA decisions frame this story. Regulatory relevance is medium for obesity, with MariTide and maridebart cafraglutide most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.
Key Takeaways
- MariTide achieved up to ~20% average weight loss at 52 weeks in people with obesity without Type 2 diabetes, compared with 2.6% in placebo.
- In the obesity-with-Type 2 diabetes cohort, MariTide showed up to ~17% average weight loss versus 1.4% placebo.
- MariTide is dosed monthly or less frequently.
- Amgen is running Phase 3 trials in obstructive sleep apnea, cardiovascular outcomes, and heart failure with preserved or mildly reduced ejection fraction.
IntelligenceCompetitive Intelligence
Competitive pressure is high. Amgen reshape positioning, formulary leverage, and partnership options. Benchmark pipeline differentiation and regional market access assumptions against this development.
Phase 2 Efficacy and Placebo Control
The Phase 2 trial of once-monthly maridebart cafraglutide reported up to approximately 20% average weight loss in participants with obesity but without Type 2 diabetes. Placebo-treated participants in that same cohort experienced 2.6% weight loss.
In the subgroup with both obesity and Type 2 diabetes, MariTide demonstrated up to approximately 17% average weight loss. The trial included placebo controls in both arms, establishing a clear separation between active drug and control.
MariTide achieved this weight reduction at 52 weeks without hitting a plateau, suggesting continued efficacy through the trial's primary endpoint.
IntelligenceMarket Signals
Commercial pull is medium and investment relevance medium for obesity. Expect implications for pricing, access, and launch sequencing.
Dosing and Clinical Development Pipeline
MariTide is a monthly or less frequently dosed obesity treatment. Amgen's Phase 3 development strategy extends beyond obesity. The company is recruiting for a Phase 3 trial of maridebart cafraglutide in obstructive sleep apnea in patients not on positive airway pressure therapy and a Phase 3 trial in obstructive sleep apnea patients already on PAP therapy. The company is also evaluating the drug in a Phase 3 cardiovascular outcomes trial in participants with atherosclerotic cardiovascular disease and overweight or obesity and a Phase 3 trial in heart failure with preserved or mildly reduced ejection fraction and obesity.
Amgen is also planning a Phase 3 switch trial comparing maridebart cafraglutide to GLP-1 receptor agonists in adults with obesity or overweight, and recruiting for a Phase 2 trial in elevated liver fat and obesity or overweight.
IntelligenceStrategic Takeaways
MariTide achieved up to ~20% average weight loss at 52 weeks in people with obesity without Type 2 diabetes , compared with 2.6% in placebo. In the obesity-with-Type 2 diabetes cohort, MariTide showed up to ~17% average weight loss versus 1.4% placebo. MariTide is dosed monthly or less frequently .
Trial Snapshot
| Trial | Title | Status | Phase | Sponsor |
|---|---|---|---|---|
| NCT07226765 | Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | RECRUITING | PHASE3 | Amgen |
| NCT07037433 | Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | RECRUITING | PHASE3 | Amgen |
| NCT07037459 | Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | RECRUITING | PHASE3 | Amgen |
| NCT07225686 | Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | RECRUITING | PHASE3 | Amgen |
| NCT07575399 | Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) | NOT_YET_RECRUITING | PHASE3 | Amgen |
IntelligenceEvidence Quality
Grounded in 1 peer-reviewed source.
Competitor Matrix
| Company / Program | Indication | Active trials |
|---|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | obesity | 3 |
| Chendu DIAO Pharmaceutical Group CO., LTD. | obesity | 1 |
| National Human Genome Research Institute (NHGRI) | obesity | 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | obesity | 1 |
| Eli Lilly and Company | obesity | 1 |
| Shandong Suncadia Medicine Co., Ltd. | obesity | 1 |
Timeline
- Recruiting trial NCT07226765 (PHASE3)
- Recruiting trial NCT07037433 (PHASE3)
- Recruiting trial NCT07037459 (PHASE3)
- Recruiting trial NCT07225686 (PHASE3)
- Not_Yet_Recruiting trial NCT07575399 (PHASE3)
Frequently Asked Questions
What weight loss did MariTide show in the Phase 2 trial?
MariTide demonstrated up to approximately 20% average weight loss at 52 weeks in participants with obesity without Type 2 diabetes, and up to approximately 17% average weight loss in participants with obesity and Type 2 diabetes.
What is once-monthly maridebart cafraglutide for the treatment of obesity?
Once-monthly maridebart cafraglutide is the investigational name for MariTide, evaluated in a Phase 2 trial that reported substantial weight reductions in participants with obesity with or without Type 2 diabetes. MariTide is dosed monthly or less frequently.
What Phase 3 trials is Amgen running with MariTide?
Amgen is conducting multiple Phase 3 programs. One Phase 3 trial is evaluating maridebart cafraglutide in obstructive sleep apnea in patients not on positive airway pressure therapy, while another is examining cardiovascular outcomes in participants with atherosclerotic cardiovascular disease and overweight or obesity. A third Phase 3 trial is testing the drug in heart failure with preserved or mildly reduced ejection fraction and obesity. Additionally, Amgen is recruiting for a Phase 3 trial in obstructive sleep apnea patients already on PAP therapy.
What was the placebo weight loss in the Phase 2 trial?
In the obesity-without-Type 2 diabetes cohort, placebo-treated participants experienced 2.6% average weight loss. The trial included placebo controls to establish the drug's efficacy relative to standard care.
Related profiles
Related coverage
Continue Exploring
Jump into the entities behind this story.
Ask AI About obesity
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Follow MariTide developments
FDA obesity alerts and MariTide pipeline updates, every Monday.
- Sources analyzed
- 1
- Evidence strength
- 87/100
- Last verified
- Jun 7, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
High source quality · grounded in cited primary and secondary sources.
This article follows our editorial standards. Report a correction via editorial contact.
About the Author
Continue Your Research
Industry Reports & Whitepapers
- Ensuring Compatibility for GLP-1-based Drugs — The rise of GLP-1 agonists like Semaglutide demands innovative ready-to-use cartridges to enhance de…